Joshua Ellenhorn, MD
Principal Investigator Clinical Trials, Cedars-Sinai Hospital, Los Angeles, CA
Joshua D.I. Ellenhorn, MD, serves as the Lead Principal Investigator for our upcoming multi-center clinical validation trail. Dr. Ellenhorn is a leading expert in Surgical Oncology, specializing in the surgical treatment of cancer. He is Clinical Professor of Surgery at Cedars-Sinai Medical Center and Adjunct Professor at the John Wayne Cancer Center. He is ranked by US News & World Report among the top 1% of Surgeons in the United States and ranked as a Super Doctor in Los Angeles. He is a medical educator, having trained over 60 surgical oncologists. A nationally recognized leader in surgery, surgical education, and cancer research, Dr. Ellenhorn is dedicated to providing the highest quality of surgical care with an emphasis on a personalized approach to the individual patient.
Dr. Ellenhorn practiced for over 18 years at the City of Hope National Medical Center and was Professor and Chief of the Division of General and Oncologic Surgery and was director of the nationally recognized Surgical Oncology Training Program. His many achievements include pioneering the use of minimally invasive and robotic techniques to treat gastrointestinal malignancies. He has been in the forefront of breast cancer treatment, promoting highly innovative techniques such as intraoperative radiation therapy and skin and nipple sparing techniques for breast cancer treatment. In addition to his clinical and educational work, Dr. Ellenhorn directed an active research laboratory. His laboratory worked to develop new cancer vaccines that can stimulate the immune system to identify and eliminate cancer cells.
William B. Farrar, MD
Acting Chief Medical Officer -The Ohio State University JamesCare Comprehensive Breast Center
William B. Farrar, MD, The Dr. Arthur G. and Mildred C. James Professor in Surgical Oncology and chief, Division of Surgical Oncology, and director of the new 220,000 square foot JamesCare Comprehensive Breast Center is the sponsor for Cyrcadia Health’s final validation clinical trial.
Dr. Farrar is one of the nation’s foremost experts in breast cancer detection and treatment, as well as a leader in the central Ohio cancer community. Having trained as a surgical resident under Dr. Arthur G. James, the founder and namesake of our cancer hospital, Dr. Farrar has played an invaluable role in Ohio State’s emergence as a national leader in cancer care.
Working with physicians and administrators throughout the breast cancer program, Dr. Farrar has develop and implement the clinical vision and strategy for the Center. He oversees all aspects of clinical breast services and ensure the delivery of multidisciplinary, multimodality care in one location. He is also be responsible for continued improvement of patient outcomes and for the creation of a unique patient experience that boosts satisfaction levels and exceeds quality and safety goals. Finally, as the originator for the initial Cyrcadia Health trial, Dr. Farrar will see the final successful patient testing completed leading to Cyrcadia Health’s FDA clinical 510K filing in late 2014.
Katherine Sutherland, MD, FACOG
Principal Investigator - OB/GYN and Medical Director for Genomics Medical Institute of El Camino Hospital, Mt. View, CA
Dr. Sutherland, born in St. Petersburg, FL, attended Emory University in Atlanta for her BS and Harvard for her MS in Chemistry. She then went to Stanford for medical school and continued there for internship and residency in OB/GYN. She formed what was to become Women Physician’s Medical Group in 1983. She was Board Certified by the American College of OB/GYN in 1985 and is a fellow of the American College of OB/GYN (FACOG). She has served as chairman of the El Camino Hospital department of OB/GYN.
Dr. Sutherland has a special interest in management of menopause, female sexuality, and minimally invasive gynecologic surgery with a major focus on preventative women’s health. She has also been serving as the medical director of the Genomics Medical Institute (GMI) of El Camino Hospital since August, 2011. In this position, she works with the genetic counselors and fellow physicians to integrate genomic medicine into clinical practice.
Dr. Sutherland is married and has two daughters. Her hobbies include travel, genealogy, hiking, and gardening. She is a breast cancer survivor and does volunteer work for cancer organizations.
Dr. Imtiaz Qureshi
Principal Investigator - Medical Director and Chief of Radiology, El Camino Hospital, Mt. View CA
Dr. Imtiaz Qureshi is the Chief of Imaging and Medical Director at El Camino Hospital. He trained at elite Institutions like Yale University and Stanford University. He specializes in Oncologic Imaging and Neuroradiology. His special interest is early cancer detection and development of cutting edge medical devices in Imaging. He is Principal Investigator of several Clinical Trials in the Early Cancer Detection field.
Barb Dehn, RN, MS, NP
Medical Board Advisor
Known as “Nurse Barb” to legions of her television and blog followers, Ms. Dehn is the host of Nurse Barb’s Daily Dose which is broadcast throughout the country on ABC and The Live Well Network. She is a practicing women’s health nurse practitioner, award winning author and a nationally recognized health expert. Ms. Dehn holds a BS from Boston College and earned her master’s degree at the University of California, San Francisco. An in-demand and popular national speaker on all aspects of women’s health, she also lectures at Stanford and is a go-to health expert on television. She has appeared on CBS, CNN, Good Morning America Now and NBC’s iVillageLive. Nurse Barb’s first book, A Hot Guide to a Cool, Sexy Menopause (Basic Health Publications) was released in September 2014.
“Women are in great need of new technology, such as Cyrcadia Health’s, as we continue our efforts to bolster early breast cancer detection,” said Dehn. “This affordable and convenient Cyrcadia Health BodyMedia technology could provide a significant step towards meeting this goal. I am pleased to be a part of this endeavor and look forward to help introduce this innovative concept to patients and clinicians worldwide.”
Bonnie Rush, RT(R)(M)(QM)
Medical Board Advisor
Ms. Rush is a recognized expert in the breast imaging arena and the founder and president of Breast Imaging Specialists (BIS) of San Diego, Calif., a company focused on aiding imaging facilities to optimize their breast cancer early detection programs. Ms Rush was recognized by her imaging peers in an article titled “Working Wonders”, highlighting Bonnie’s dedication, expertise and involvement in the breast imaging arena.
Due to her ability to share salient information of value to imaging personnel, Bonnie is a requested speaker at local, regional and national imaging conferences. Ms. Rush authored the definitive explanation of the Mammography Quality Standards Act and is an expert witness in regulatory issues. She is considered an subject matter expert and is often quoted in breast imaging articles.
Her volunteer activities are numerous and have included many firsts including; establishing the first low-cost mammography screening program in San Diego, launching of the San Diego Breast Cancer Early Detection Program, founding the Mammography Society of San Diego and being named the first Director at Large in Mammography for her State Society.
Ms. Rush was personally impacted by dense breast tissue leading to a delayed diagnosis of invasive breast cancer in 2012. Her drive now is to advance early detection for all women with a special focus on “changing the destiny of those with breast density”. In that effort, she has added another first - first AHRA (Association of Medical Imaging Management) liaison to the Are You Dense Advocacy, Inc. to advance notification of the increased risk and masking of cancers in those with dense breasts.
Bonnie joined our company in order to reach her goal of optimizing early detection for all women. “I am so pleased to have this opportunity to work with such an extraordinary team of dedicated (and smart) individuals,” said Ms. Rush. “The goal is so exciting – the motivating driver to raise the bar on early detection and thus to save lives – with the appreciated potential of economic success. I could not ask for more positive reasons to say yes to join in this effort to advance this novel technology.”